EMFACE Surpasses One Million Treatments, Redefining Non-Invasive Facial Aesthetics

EMFACE Achieves a Remarkable Milestone in Aesthetic Treatments

EMFACE, a pioneering non-invasive facial treatment developed by BTL, has made headlines by exceeding one million treatments worldwide in just under two years. This rapid ascent has made it the fastest-growing procedure in its category, revolutionizing the way we view facial rejuvenation.

A Unique Approach to Facial Aesthetics

Introduced in 2022, EMFACE is the first operator-independent procedure that non-invasively targets facial muscles while simultaneously enhancing skin quality. According to Dr. Yael Halaas, a facial plastic surgeon in New York, "The ability to stimulate lifting muscles allows us to elevate facial features from within, something traditional injectables or energy-based devices couldn't achieve."

One of the most significant distinguishing features of EMFACE is its non-invasive nature. The procedure does not require needles, involves zero downtime, and is virtually painless, leading to widespread recognition and adoption by both healthcare professionals and patients alike.

Innovations that Enhance Treatment

In the past year, EMFACE has expanded its capabilities by introducing specialized applicators designed for the submental area and under the eyes, thereby enhancing its versatility. The latest applicators for the periocular area received overwhelmingly positive feedback from medical experts during their launch at the global IMCAS conference in Paris in January 2025. Dr. Kyungkook Hong, a certified dermatologist from Seoul, emphasizes that "EMFACE is not just a procedure; it's a multifunctional facial platform that allows us to address different areas according to each patient's unique needs. It’s a game-changer for those seeking a more natural facial rejuvenation."

Global Expansion and Industry Impact

As EMFACE continues to gain traction, more practitioners are incorporating it into their treatment offerings. Its ability to complement existing injectable products makes it a key player in comprehensive facial rejuvenation plans, providing patients with a non-invasive option for enhanced results.

CEO Tomas Schwarz of BTL stated, "Reaching one million treatments in just two years underscores the revolutionary nature of EMFACE technology and the value it brings to healthcare professionals. We are committed to further developing this platform and advancing non-invasive facial treatments in the years to come."

The Future of Non-Invasive Facial Treatments

With less than two years under its belt, EMFACE symbolizes the future of non-invasive facial aesthetics. The rapid growth and influx of treatments emphasize the rising demand for solutions that can offer enhanced results without traditional surgical methods. This innovative technology not only empowers patients in their quest for youthful radiance but also reshapes the industry standards for facial treatments.

In conclusion, as EMFACE sets a new benchmark in the field, continued innovation and understanding of patient needs will be key drivers in shaping the future landscape of non-invasive facial aesthetic procedures. For more detailed information about EMFACE and its revolutionary technology, visit www.emface.fr.

About BTL

Founded in 1993, BTL has emerged as one of the world's leading manufacturers of medical equipment. With a committed workforce of over 3,000 employees, including 500 engineers, BTL provides advanced non-invasive solutions for body shaping, skin tightening, and other aesthetic medical treatments. Its product portfolio includes notable brands such as EMSCULPT NEO®, EMFACE®, and EMSELLA®, along with proprietary procedures like HIFEM® and EXOTMS™. For further details, visit www.btlaesthetics.fr.